News from the FDA/CDC

FDA approves autoinjector pen for Humira biosimilar, Cyltezo


 

The U.S. Food and Drug Administration on May 22 approved a new autoinjection option for adalimumab-adbm (Cyltezo), a biosimilar to AbbVie’s adalimumab (Humira), ahead of Cyltezo’s commercial launch on July 1, 2023.

FDA icon

Cyltezo was approved by the FDA in 2017 as a prefilled syringe and was the first biosimilar deemed to be interchangeable with Humira in 2021. It is indicated to treat multiple chronic inflammatory conditions, including rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, and hidradenitis suppurativa. This new design, which features one-button, three-step activation, has been certified as an “Ease of Use” product by the Arthritis Foundation, Boehringer Ingelheim said in a press release. The 40-mg, prefilled Cyltezo Pen will be available in two-, four-, and six-pack options.

“The FDA approval of the Cyltezo Pen is great news for patients living with chronic inflammatory diseases who may prefer administering the medication needed to manage their conditions via an autoinjector,” said Stephen Pagnotta, the executive director and biosimilar commercial lead at Boehringer Ingelheim in a statement; “we’re excited to be able to offer the Cyltezo Pen as an additional option to patients at Cyltezo’s launch on July 1.”

A version of this article first appeared on Medscape.com.

Recommended Reading

Strong link between polycyclic aromatic hydrocarbons and raised rheumatoid arthritis risk
MDedge Rheumatology
Joint damage repair: A rare phenomenon in early RA
MDedge Rheumatology
Tofacitinib withdrawal not a universal option for all patients with RA in remission
MDedge Rheumatology
Factors guiding sustained remission after withdrawal of combination therapy in RA
MDedge Rheumatology
HPV infection, HPV immunization, and RA prevalence: What is the link?
MDedge Rheumatology
No evidence to indicate significantly higher risk for cancer with JAKi vs bDMARD in RA
MDedge Rheumatology
Mendelian randomization study supports causal association between RA and coronary atherosclerosis
MDedge Rheumatology
Comparable efficacy of TNFi and IL-6Ri in b/tsDMARD-experienced patients with RA
MDedge Rheumatology
RA, seropositivity, and risk for Parkinson disease: Is there a link?
MDedge Rheumatology
Worse outcomes among elderly patients with RA undergoing percutaneous coronary intervention
MDedge Rheumatology